Apogee Therapeutics Inc (APGE)

Currency in USD
135.07
-0.01(-0.01%)
Real-time Data·
Advertisement
Showing Apogee Therapeutics historical data. For real-time data please try another search
Fair Value
Day's Range
135.06135.09
52 wk Range
35.39135.09
Key Statistics
Prev. Close
135.07
Open
135.08
Day's Range
135.06-135.09
52 wk Range
35.39-135.09
Volume
5.14M
Average Volume (3m)
2.79M
1-Year Change
263.7759%
Book Value / Share
15.95
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APGE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
134.78
Downside
-0.22%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Apogee Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

1 Buy
10 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 134.78
(-0.22% Downside)

Earnings

Latest Release
10/08/2026
EPS / Forecast
-1.14 / -0.70
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare APGE to Peers and Sector

Metrics to compare
APGE
Peers
Sector
Relationship
P/E Ratio
−34.6x0.0x−0.4x
PEG Ratio
6.500.000.00
Price/Book
8.5x0.0x2.6x
Price / LTM Sales
-0.0x3.1x
Upside (Analyst Target)
−0.1%0.0%49.6%
Fair Value Upside
Unlock0.0%7.1%Unlock

Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
29.95M39.72%4.05B
Other Institutional Investors
60.04M60.28%8.11B
Public Companies & Retail Investors
0.000.00%0.00
Total
89.99M100.00%12.15B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
VR Management, LLC11.26%8,493,3211,147,193
Fairmount Funds Management LLC8.96%6,755,727912,496

People Also Watch

74.02
CGON
-0.42%
53.645
CLMT
+0.27%
25.300
NAMS
-2.13%
61.20
MBX
-0.36%
84.95
CRNX
+0.13%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.